Regencell Bioscience Holdings Ltd (RGC)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · Hong Kong

Regencell Bioscience Holdings Ltd is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.

Intrinsic value, DCF valuation, financial health and value investing analysis for the Regencell Bioscience Holdings Ltd stock.

Our verdict on RGC

Not valued: We cannot value this company yet.

ETFs with the most weight in RGC

• Fidelity Nasdaq Composite Index ETF (ONEQ): 0.0% of the fund

Browse

• Stocks in Hong Kong

Peers in Drug Manufacturers - Specialty & Generic

• Takeda Pharmaceutical Co ADR (TAK)
• Teva- Pharmaceutical Industries Ltd (TEVA)
• Haleon plc ADR (HLN)
• Zoetis Inc (ZTS)
• United Therapeutics Corp (UTHR)
• Viatris Inc (VTRS)
• Neurocrine Biosciences Inc (NBIX)
• Dr. Reddy's Laboratories Ltd ADR (RDY)

All 84 Drug Manufacturers - Specialty & Generic stocks

Cheaper than RGC in Drug Manufacturers - Specialty & Generic

• Emergent Biosolutions Inc (EBS): undervalued, 80% margin of safety
• Biocryst Pharmaceuticals Inc (BCRX): undervalued, 78% margin of safety
• Collegium Pharmaceutical Inc (COLL): undervalued, 74% margin of safety
• Ironwood Pharmaceuticals Inc (IRWD): undervalued, 73% margin of safety
• ANI Pharmaceuticals Inc (ANIP): undervalued, 60% margin of safety
• Amphastar Pharmaceuticals Inc (AMPH): undervalued, 44% margin of safety

35 more in this industry show a wider margin of safety.

Is RGC undervalued or overvalued?

We do not publish a verdict on RGC yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of RGC?

We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.